October 24, 2017 07:33 AM EDT
Financing
R&D

Go­ing all in: Bio­gen com­mits an ex­tra $500M to Alzheimer’s block­buster hope­ful ad­u­canum­ab

John Carroll

Editor & Founder

Bio­gen CEO Michel Vounatsos is go­ing all in on his late-stage Alzheimer’s drug ad­u­canum­ab.

The big biotech said to­day that it paid Neurim­mune, which out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times